Last updated on July 2019

Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma


Brief description of study

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma

Detailed Study Description

This is a regional, multicentre, randomized, double-blind, placebo controlled, parallel group, phase 3 study designed to evaluate the efficacy and safety of 210 mg Q4W (SC) of tezepelumab in adults with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 396 subjects will be randomized regionally (China/non-China). Subjects will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.

Clinical Study Identifier: NCT03927157

Find a site near you

Start Over

Research Site

Changchun, China
  Connect »

Research Site

Chongqing, China
  Connect »

Research Site

Guangzhou, China
  Connect »

Research Site

Shengyang, China
  Connect »

Research Site

Shijiazhuang, China
  Connect »

Research Site

Zhengzhou, China
  Connect »

Research Site

Cheongju-si, Korea, Republic of
  Connect »

Research Site

Daegu, Korea, Republic of
  Connect »

Research Site

Jeonju-si, Korea, Republic of
  Connect »

Research Site

Seoul, Korea, Republic of
  Connect »

Research Site

Suwon-si, Korea, Republic of
  Connect »

Research Site

Iloilo City, Philippines
  Connect »

Research Site

Quezon City, Philippines
  Connect »